Total Payments
$412.41
2024 Payments
$33.25
Companies
10
Transactions
11
Medicare Patients
11,891
Medicare Billing
$3.9M
Payment Breakdown by Category
Food & Beverage$318.21 (77.2%)
Education$94.20 (22.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $318.21 | 8 | 77.2% |
| Education | $94.20 | 3 | 22.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $86.42 | 1 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $81.56 | 2 | $0 (2017) |
| AVEO Pharmaceuticals, Inc. | $69.99 | 1 | $0 (2023) |
| Tactile Systems Technology Inc | $56.17 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $33.25 | 1 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $23.27 | 1 | $0 (2022) |
| ABBVIE INC. | $19.54 | 1 | $0 (2023) |
| BeiGene USA, Inc. | $18.00 | 1 | $0 (2020) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33.25 | 1 | Novartis Pharmaceuticals Corporation ($33.25) |
| 2023 | $89.53 | 2 | AVEO Pharmaceuticals, Inc. ($69.99) |
| 2022 | $79.44 | 2 | Tactile Systems Technology Inc ($56.17) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $18.00 | 1 | BeiGene USA, Inc. ($18.00) |
| 2019 | $86.42 | 1 | Celgene Corporation ($86.42) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
| 2017 | $81.56 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($81.56) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/21/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug), LUTATHERA | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Oncology | ||||||
| 05/25/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $69.99 | General |
| Category: Oncology | ||||||
| 12/08/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $56.17 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 05/04/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 06/10/2020 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 05/13/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $86.42 | General |
| Category: Hematology / Oncology | ||||||
| 04/11/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 06/20/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $68.23 | General |
| Category: Oncology | ||||||
| 06/20/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 66 | 3,133 | 66,432 | $4.4M | $886,104 |
| 2022 | 57 | 2,898 | 70,379 | $3.8M | $898,235 |
| 2021 | 65 | 3,129 | 102,440 | $5.4M | $1.3M |
| 2020 | 59 | 2,731 | 75,340 | $4.1M | $815,972 |
Total Patients
11,891
Total Services
314,591
Medicare Billing
$3.9M
Procedure Codes
247
All Medicare Procedures & Services
247 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 13,500 | $2.0M | $584,208 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 131 | 331 | $120,249 | $44,088 | 36.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 112 | 313 | $261,189 | $31,505 | 12.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 22 | 9,695 | $203,595 | $22,631 | 11.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 242 | $65,175 | $22,384 | 34.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 13 | 288 | $415,872 | $20,477 | 4.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 201 | 282 | $51,141 | $17,436 | 34.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 35 | 11,310 | $101,790 | $15,475 | 15.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 17 | 15,000 | $75,000 | $13,177 | 17.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 36 | 160 | $11,200 | $11,182 | 99.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 270 | 1,267 | $44,345 | $9,634 | 21.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 172 | 785 | $48,670 | $8,125 | 16.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 45 | 128 | $52,111 | $6,449 | 12.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 88 | 483 | $50,715 | $5,811 | 11.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $19,901 | $5,303 | 26.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 210 | 584 | $11,096 | $4,906 | 44.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 49 | $14,916 | $4,529 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $18,270 | $4,472 | 24.5% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 11 | 24 | $23,664 | $4,277 | 18.1% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 11 | 1,295 | $160,580 | $4,192 | 2.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 67 | $16,694 | $3,645 | 21.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 49 | $10,340 | $3,011 | 29.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 65 | $19,760 | $2,939 | 14.9% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 111 | 216 | $12,528 | $2,872 | 22.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 68 | 123 | $18,696 | $2,770 | 14.8% |
About Dr. Joshua Morales, MD
Dr. Joshua Morales, MD is a Hematology & Oncology healthcare provider based in Roanoke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2010. The National Provider Identifier (NPI) number assigned to this provider is 1063731016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Morales, MD has received a total of $412.41 in payments from pharmaceutical and medical device companies, with $33.25 received in 2024. These payments were reported across 11 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($318.21).
As a Medicare-enrolled provider, Morales has provided services to 11,891 Medicare beneficiaries, totaling 314,591 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 247 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Roanoke, VA
- Active Since 05/28/2010
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063731016
Products in Payments
- Revlimid (Drug) $86.42
- Stivarga (Drug) $81.56
- FOTIVDA (Drug) $69.99
- Flexitouch Plus (Device) $56.17
- PLUVICTO (Drug) $33.25
- NERLYNX (Drug) $23.27
- VENCLEXTA (Drug) $19.54
- BRUKINSA (Drug) $18.00
- ADCETRIS (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roanoke
Amanda Gillespie-Twardy, M.d, M.D
Hematology & Oncology — Payments: $15,362
Hematology & Oncology $15,362
Mark Kochenderfer, Md, MD
Hematology & Oncology — Payments: $12,819
Hematology & Oncology $12,819
Dr. Padmaja Mallidi, M.d, M.D
Hematology & Oncology — Payments: $1,580
Hematology & Oncology $1,580
Dr. Harry Mccoy, M.d, M.D
Hematology & Oncology — Payments: $544.52
Hematology & Oncology $544.52
Mrs. Kirsten Hinson, Fnp-C, FNP-C
Hematology & Oncology — Payments: $421.40
Hematology & Oncology $421.40
Dr. William Fintel, M.d, M.D
Hematology & Oncology — Payments: $388.95
Hematology & Oncology $388.95